Clinical Trials Logo

Filter by:
NCT ID: NCT02659631 Terminated - Neoplasms Clinical Trials

PF-06671008 Dose Escalation Study in Advanced Solid Tumors

Start date: April 28, 2016
Phase: Phase 1
Study type: Interventional

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, CRC or NSCLC.

NCT ID: NCT02659501 Terminated - Breast Cancer Clinical Trials

Liposomal Bupivacaine in Implant Based Breast Reconstruction

Start date: July 2015
Phase: N/A
Study type: Interventional

Objectives: 1. To evaluate the effect of liposomal bupivacaine on postoperative pain levels. 2. To evaluate the effect of liposomal bupivacaine on postoperative opioid consumption and opioid related adverse events. 3. To evaluate the effect of liposomal bupivacaine on length of hospital stay. 4. To evaluate the effect of liposomal bupivacaine on patient satisfaction with postoperative pain control. 5. To evaluate the effect of liposomal bupivacaine on overall patient satisfaction.

NCT ID: NCT02659202 Terminated - Heart Failure Clinical Trials

Spinal Stimulation During Exercise in Heart Failure

Start date: June 2016
Phase: N/A
Study type: Interventional

The purpose of this proposal is to determine whether epidural spinal cord stimulation can modulate cardiovascular control during exercise in Heart Failure patients.

NCT ID: NCT02658916 Terminated - Clinical trials for Supranuclear Palsy, Progressive

Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

Start date: February 22, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and tolerability of multiple intravenous (IV) infusions of BIIB092 in participants with Progressive Supranuclear Palsy (PSP). The study will also assess the pharmacodynamic (PD) effects of BIIB092 on cerebrospinal fluid (CSF) N-terminal tau, pharmacokinetics (PK), and immunogenicity of BIIB092 in participants with PSP.

NCT ID: NCT02658877 Terminated - Asthma Clinical Trials

Sputum-derived Cellular Targets After Xolair (Omalizumab)

Start date: January 2016
Phase: Phase 4
Study type: Interventional

The primary purpose of this study is to identify additional mechanisms of action of omalizumab that will lead to improved stratification of patients for treatment. Understanding the response of specific innate immune effector cells in the lung can provide clues to these questions. Investigators will use non-invasive measures of a discrete cell population to examine the downstream effects of omalizumab treatment in the lung. Information derived from these studies will help clarify mechanisms of action of omalizumab and help identify potential tools for patient endotyping and stratification for therapeutic interventions.

NCT ID: NCT02658812 Terminated - Clinical trials for Recurrent Breast Carcinoma

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

Start date: August 1, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well talimogene laherparepvec works in treating patients with breast cancer that has come back and cannot be removed by surgery. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing.

NCT ID: NCT02658123 Terminated - Ileostomy Clinical Trials

Reducing Readmissions in High-Risk Ostomates

Start date: April 2016
Phase: N/A
Study type: Interventional

Preventing complications and readmission after ostomy surgery will decrease the cost of healthcare, improve patient safety, reduce the cost of durable medical equipment required by ostomates, ensure continued specialized care is available, and potentially improve both short and long-term quality of life (QOL) for patients by reducing morbidity and mortality associated with ostomy surgery. The purpose of this study is to measure the effectiveness of patient centered interventions/care pathways and to determine the impact on healthcare utilization, 30-day hospital readmissions, and QOL.

NCT ID: NCT02658084 Terminated - Breast Cancer Clinical Trials

Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

Start date: April 12, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The study proposes to evaluate the safety and efficacy of the combination of trastuzumab emtansine (T-DM1) and vinorelbine in HER2+ metastatic breast cancer patients.

NCT ID: NCT02657421 Terminated - Clinical trials for Degenerative Disc Disease

OLIF25™ /OLIF51™ Study

Start date: November 2015
Phase:
Study type: Observational [Patient Registry]

The purpose of this single-arm observational study is to observe and document clinical outcomes of the OLIF25™ and OLIF51™ procedures in patients diagnosed with degenerative disc disease or degenerative scoliosis, and report the rate of adverse events of interest through the 24 months follow-up visit.

NCT ID: NCT02657369 Terminated - Clinical trials for Thyroid Carcinoma, Anaplastic

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Start date: July 7, 2016
Phase: Phase 2
Study type: Interventional

The primary purpose of the study is to evaluate objective response rate ([ORR]: complete response [CR] and partial response [PR]) by investigator review in participants with anaplastic thyroid cancer (ATC) treated with lenvatinib.